NO933037D0 - Fremstilling og anvendelse av formalinavlivede e. coliorganismer som uttrykker kolonisasjonsfaktor-antigen (cfa), til vaksinasjon mot tarminfeksjon/diare hos mennesker foraarsaket av tarmtoksigenet e. coli-bakterier - Google Patents
Fremstilling og anvendelse av formalinavlivede e. coliorganismer som uttrykker kolonisasjonsfaktor-antigen (cfa), til vaksinasjon mot tarminfeksjon/diare hos mennesker foraarsaket av tarmtoksigenet e. coli-bakterierInfo
- Publication number
- NO933037D0 NO933037D0 NO933037A NO933037A NO933037D0 NO 933037 D0 NO933037 D0 NO 933037D0 NO 933037 A NO933037 A NO 933037A NO 933037 A NO933037 A NO 933037A NO 933037 D0 NO933037 D0 NO 933037D0
- Authority
- NO
- Norway
- Prior art keywords
- coli
- colonization factor
- equivalented
- formaline
- cfa
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/848—Escherichia
- Y10S435/849—Escherichia coli
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9100556A SE9100556D0 (sv) | 1991-02-26 | 1991-02-26 | Preparation and use of formalin-killed colonization-factor-antigen (cfa)-expressing e coli organisms for vaccination against enteric infection/diarrhea caused by enterotoxigenic e coli bacteria in humans |
PCT/SE1992/000110 WO1992014487A1 (en) | 1991-02-26 | 1992-02-25 | Preparation and use of formalin-killed colonization-factor-antigen (cfa)-expressing e. coli organisms for vaccination against enteric infection/diarrhea caused by enterotoxigenic e. coli bacteria in humans |
Publications (3)
Publication Number | Publication Date |
---|---|
NO933037D0 true NO933037D0 (no) | 1993-08-25 |
NO933037L NO933037L (no) | 1993-08-25 |
NO307867B1 NO307867B1 (no) | 2000-06-13 |
Family
ID=20381987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO933037A NO307867B1 (no) | 1991-02-26 | 1993-08-25 | FremgangsmÕte for fremstilling av et vaksinepreparat mot tarminfeksjon hos mennesker forÕrsaket av enterotoksigene E. coli- bakterier |
Country Status (22)
Country | Link |
---|---|
US (1) | US6558678B1 (no) |
EP (1) | EP0573527B1 (no) |
JP (1) | JP3169608B2 (no) |
KR (1) | KR100221452B1 (no) |
AT (1) | ATE170755T1 (no) |
AU (1) | AU663864B2 (no) |
BG (1) | BG61683B1 (no) |
BR (1) | BR9205677A (no) |
CA (1) | CA2104877C (no) |
CZ (1) | CZ281556B6 (no) |
DE (1) | DE69226944T2 (no) |
DK (1) | DK0573527T3 (no) |
ES (1) | ES2123550T3 (no) |
FI (1) | FI108775B (no) |
HU (1) | HU213924B (no) |
NO (1) | NO307867B1 (no) |
OA (1) | OA09865A (no) |
RO (1) | RO109819B1 (no) |
RU (1) | RU2127121C1 (no) |
SE (1) | SE9100556D0 (no) |
SK (1) | SK280919B6 (no) |
WO (1) | WO1992014487A1 (no) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7118758B1 (en) * | 1997-01-24 | 2006-10-10 | The United States Of America As Represented By The Secretary Of The Army | Transformed bacteria producing CS6 antigens as vaccines |
SE9401921D0 (sv) * | 1994-06-03 | 1994-06-03 | Sbl Vaccin Ab | A method of cultivating bacteria |
US7404961B2 (en) | 1996-08-02 | 2008-07-29 | The United States Of America As Represented By The Secretary Of The Army | Peptides responsive to antibodies against consensus peptide of the CS4-CFA/I family proteins |
US7094883B1 (en) | 1996-08-02 | 2006-08-22 | The United States Of America As Represented By The Secretary Of The Army | Monoclonal antibody which agglutinates E. coli having the CS4-CFA/I family protein |
US5994078A (en) * | 1997-07-31 | 1999-11-30 | Maine Medical Center | Stable encapsulated reference nucleic acid and method of making |
SE515285C2 (sv) * | 1998-12-18 | 2001-07-09 | Sbl Vaccin Ab | Oralt vaccin mot diarré |
GB0121998D0 (en) | 2001-09-11 | 2001-10-31 | Acambis Res Ltd | Attenuated bacteria useful in vaccines |
NZ547156A (en) * | 2003-10-31 | 2009-08-28 | Univ British Columbia | Attenuation of A/E pathogen virulence by modulating expression of NleA |
WO2007089205A1 (en) * | 2006-02-01 | 2007-08-09 | Sbl Vaccin Ab | Colonization factor (cf) antigens of enterotoxigenic escherichia coli in recombinant bacteria |
EP2711013A4 (en) * | 2011-05-18 | 2015-03-04 | Ajinomoto Kk | IMMUNSTIMULANDS FOR ANIMALS, FEED THEREFOR AND MANUFACTURING PROCESS THEREFOR |
WO2013009843A1 (en) * | 2011-07-11 | 2013-01-17 | Camas Incorporated | Compositions against bacterial toxins |
AU2011376755B2 (en) * | 2011-09-12 | 2016-09-29 | Scandinavian Biopharma Holding Ab | Vaccine for protection against ETEC induced diarrhea comprising dmLT. |
EP2750701B1 (en) | 2011-09-12 | 2015-10-21 | Scandinavian Biopharma Holding AB | Method for increasing etec cs6 antigen presentation on cell surface and products obtainable thereof |
RO132299A3 (ro) | 2017-06-06 | 2018-12-28 | Fântână Raul Sorin | Compoziţie şi metodă de preparare şi evaluare a unui imunogen complex numit i-spga, destinat producerii de proteine imunologic active () |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD62894A (no) * | ||||
DE1208038B (de) * | 1963-08-01 | 1965-12-30 | Wellcome Found | Verfahren zur Herstellung von Impfstoffen gegen Coli-Infektionen |
GB1472624A (en) | 1974-09-02 | 1977-05-04 | Canadian Patents Dev | Enteric disease vaccine |
US4338298A (en) * | 1980-04-04 | 1982-07-06 | Endowment And Research Foundation At Montana State University | Vaccine for passive immunization against enteric colibacillosis and method of use |
DK41885A (da) * | 1985-01-31 | 1986-11-13 | Slagteriernes Forskningsinst | 987p-fimbrie-producerende mikroorganisme, vaccine til immunisering af grise samt fremgangsmaade til fremstilling af vaccinen |
IL79432A (en) * | 1985-07-31 | 1992-05-25 | Univ Leland Stanford Junior | Unicellular microorganisms having invasive capability due to exogenous inv gene and vaccines comprising such microorganisms |
FI76484C (fi) | 1986-02-03 | 1988-11-10 | Osmo Norvasto | Kundstol. |
JPS6399020A (ja) | 1986-06-05 | 1988-04-30 | ベイラ− カレツジ オブ メデイシン | ワクチンとその製法 |
SU1723116A1 (ru) * | 1988-04-15 | 1992-03-30 | Оренбургский Государственный Медицинский Институт | Штамм бактерий BacILLUS SUвтILIS, используемый дл получени препарата дл профилактики и лечени воспалительных процессов и аллергических заболеваний |
KR900701152A (ko) * | 1988-09-06 | 1990-12-01 | 원본미기재 | 유전자 변환식물, 이로부터 얻어진 조성물 및 그 제조방법 |
SE9401921D0 (sv) * | 1994-06-03 | 1994-06-03 | Sbl Vaccin Ab | A method of cultivating bacteria |
-
1991
- 1991-02-26 SE SE9100556A patent/SE9100556D0/xx unknown
-
1992
- 1992-02-25 DE DE69226944T patent/DE69226944T2/de not_active Expired - Fee Related
- 1992-02-25 HU HU9302410A patent/HU213924B/hu not_active IP Right Cessation
- 1992-02-25 KR KR1019930702564A patent/KR100221452B1/ko not_active IP Right Cessation
- 1992-02-25 AU AU13308/92A patent/AU663864B2/en not_active Ceased
- 1992-02-25 CZ CS931742A patent/CZ281556B6/cs not_active IP Right Cessation
- 1992-02-25 SK SK910-93A patent/SK280919B6/sk unknown
- 1992-02-25 US US08/108,606 patent/US6558678B1/en not_active Expired - Fee Related
- 1992-02-25 CA CA002104877A patent/CA2104877C/en not_active Expired - Fee Related
- 1992-02-25 ES ES92906078T patent/ES2123550T3/es not_active Expired - Lifetime
- 1992-02-25 RU RU93053899A patent/RU2127121C1/ru not_active IP Right Cessation
- 1992-02-25 EP EP92906078A patent/EP0573527B1/en not_active Expired - Lifetime
- 1992-02-25 WO PCT/SE1992/000110 patent/WO1992014487A1/en active IP Right Grant
- 1992-02-25 RO RO93-01142A patent/RO109819B1/ro unknown
- 1992-02-25 BR BR9205677A patent/BR9205677A/pt not_active Application Discontinuation
- 1992-02-25 AT AT92906078T patent/ATE170755T1/de not_active IP Right Cessation
- 1992-02-25 JP JP50610592A patent/JP3169608B2/ja not_active Expired - Fee Related
- 1992-02-25 DK DK92906078T patent/DK0573527T3/da active
-
1993
- 1993-08-24 OA OA60404A patent/OA09865A/en unknown
- 1993-08-25 BG BG98070A patent/BG61683B1/bg unknown
- 1993-08-25 FI FI933728A patent/FI108775B/fi active
- 1993-08-25 NO NO933037A patent/NO307867B1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO933037L (no) | Fremstilling og anvendelse av formalinavlivede e. coliorganismer som uttrykker kolonisasjonsfaktor-antigen (cfa), til vaksinasjon mot tarminfeksjon/diare hos mennesker foraarsaket av tarmtoksigenet e. coli-bakterier | |
Talbot et al. | Progress in the development of mastitis vaccines | |
Jonson et al. | Vibrio cholerae expresses cell surface antigens during intestinal infection which are not expressed during in vitro culture | |
RU93053899A (ru) | Способ получения композиции вакцины, способ профилактики кишечных инфекций | |
Mukhopadhaya et al. | Role of Shigella flexneri 2a 34 kDa outer membrane protein in induction of protective immune response | |
Bratthall et al. | Antigenic variation of Streptococcus mutans colonizing gnotobiotic rats | |
Matsumoto et al. | Efficacies of alkaline protease, elastase and exotoxin A toxoid vaccines against gut-derived Pseudomonas aeruginosa sepsis in mice | |
KANEMORI et al. | The role of extracellular protease produced by Vibrio anguillarum | |
Lasaro et al. | Prime-boost vaccine regimen confers protective immunity to human-derived enterotoxigenic Escherichia coli | |
Yamaguchi et al. | Antibody formation against Salmonella flagella by an immune ribonucleic acid fraction | |
Ahmad et al. | Evaluation of Staphylococcus aureus and Streptococcus agalactiae aluminium hydroxide adjuvanted mastitis vaccine in rabbits | |
Boesman-Finkelstein et al. | Protection in rabbits induced by the Texas Star-SR attenuated A-B+ mutant candidate live oral cholera vaccine | |
US3885011A (en) | Vaccine adjuvants | |
Shaughnessy et al. | Production of Potent Inactivated Vaccines with Ultraviolet Irradiation: IV. Vaccination Against Bacillary Dysentery | |
RU2227160C1 (ru) | Штамм бактерий leptospira interrogans "митронов" серогруппы canicola для приготовления вакцины | |
Guinée et al. | Protective immunity against Vibrio cholerae infection in the rabbit | |
Yancey et al. | Motility of the pathogen and intestinal immunity of the host in experimental cholera | |
RU2190424C1 (ru) | Антигенный состав чумной химической вакцины | |
RU2285539C2 (ru) | Молекулярная бивалентная вакцина для профилактики бруцеллеза и диарей, вызванных энтеропатогенными бактериями | |
Jansen et al. | Priming and boosting of the rabbit intestinal immune system with live and killed, smooth and rough Vibrio cholerae cells | |
RU2058388C1 (ru) | Штамм бактерий vibrio cholerae eltor jnaba, используемый для иммунопрофилактики холеры | |
Chander et al. | A note: polyvalent radiovaccine against Salmonella | |
Holder et al. | Oral Pseudomonas aeruginosa immunization enhances survival in mice subsequently burned and infected with P. aeruginosa | |
Fournier | 3. Current Pandemics of Cholera and Strategy of Cholera Vaccines | |
Mackowiak | Germ warfare |